Compositions

EP4456740A1Pending Publication Date: 2024-11-06MEDA PHARMA SPA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
EP2023700379
Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-01-01
Filing Date
2023-01-02
Publication Date
2024-11-06

Smart Images

  • Figure IMGF000003_0001
    Figure IMGF000003_0001
  • Figure IMGF000003_0002
    Figure IMGF000003_0002
  • Figure IMGF000006_0001
    Figure IMGF000006_0001
Patent Text Reader

Abstract

The invention relates to solid oral compositions, comprising monascus fermented rice stabilized by adding CaCO3.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] COMPOSITIONS

[0002] The invention relates to solid oral compositions, based on monascus fermented rice standardized in monacolin K (MK), using addition of calcium carbonate for improving monacolin K stability.

[0003] BACKGROUND OF THE INVENTION

[0004] Monascus fermented rice, also known as red yeast rice (RYR), has traditionally been used as a natural food colorant and food preservative of meat and fish for centuries. It has recently become a popular dietary supplement because many of its bioactive constituents, including a series of active drug compounds, monacolins (indicated as 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) have been discovered as being capable of reducing serum cholesterol levels (Lin et al., Appl Microbiol Biotechnol 2008; 77, 965 - 973).

[0005] Among the bioactive compounds found in red yeast rice, monacolins are well known for their pharmacological effects to control hyperlipidemia. Monacolin K is considered the most efficacious compound to lower cholesterol in the plasma. It is structurally identical to lovastatin, and mevinolin (Klimek, Wang, and Ogunkanmi, P&T 2009, 34 No 6, 313-316).

[0006] It is well known that monacolin K has poor stability in red yeast rice and in pharmaceutical dosage forms. Stability analyses have shown that monacolin K was unstable during prolonged storage of red yeast rice powder particularly at high storage temperature (40-50°C) especially under atmospheric storage conditions (Sani Jirasatid et al., Journal of Food Engineering 116 (2013) 436-443).

[0007] Further studies exhibited that monacolins decreased significantly under the conditions of high humidity at high temperature (75% relative humidity (RH), 60°C) and sunlight. Monacolin K and its hydroxyl acid form would be dehydrolyzed and turned to dehydromonacolin K at high temperature (80°C) while monacolin K, J and L would be transformed into their corresponding hydroxyl acid forms under the condition of high humidity (92.5% RH, 25°C). The observations show the result that monacolins in red yeast rice powder are light-sensitive and thermal-sensitive (Yong-Guo Li,. Journal of Pharmaceutical and Biomedical Analysis 39 (2005) 82-90.

[0008] Accordingly, it is an object of the present invention to provide monacolin K in a red yeast rice formulation which shows an increased stability

[0009] SUMMARY OF THE INVENTION

[0010] The invention provides a composition comprising red yeast rice and CaCO3. Surprisingly the applicant has found that compositions comprising red yeast rice and CaCO3has improved stability showing a statistically significant effect. DEFINITIONS

[0011] The proportions of the various components of the combination are defined relative to other components. The wt% (weight percent) of a particular component, based on the other components, is the weight (mass) of the particular component, divided by the weight (mass) of based on weight of the composition, times 100 i.e. wt% single component X (based on weight of the composition Y) = x 100

[0012] Monascus fermented rice or red yeast rice is a traditional Chinese preparation of cooked white rice, being fermented with Monascus purpureus for a few days at room temperature, which results in the red colour. The red yeast rice used in the context of the present invention can be standardized in Monacolin K from 0.5 to 2.0 % (w / w).

[0013] Particularly preferred is a red yeast rice standardized in Monacolin K 1.75%.

[0014] DETAILED DESCRIPTION OF THE INVENTION

[0015] The invention provides a composition comprising red yeast rice and CaCO3(calcium carbonate).

[0016] In one embodiment, the invention provides a composition of red yeast rice standardized in monacolin K to 1 .75% w / w and CaCO3in a weight ratio of 1 to 5 to 5 to 1 .

[0017] Preferably the invention provides a composition of red yeast rice standardized in monacolin K to 1 .75% w / w and CaCO3in a weight ratio of 2 to 1 .

[0018] More preferably, the invention provides a composition of red yeast rice standardized in monacolin K to 1 .75% w / w and CaCO3in a weight ratio of 1 to 2.

[0019] More preferably, the invention provides a composition of red yeast rice standardized in monacolin K to 1 .75% w / w and CaCO3in a weight ratio of 2 to 3.

[0020] In a further embodiment, the aforementioned compositions may additionally comprise one or more components selected from Berberis aristata, phytosterols and / or phytostanols, Cynara cardunculus extract, Citrus bergamia extract, Allium sativum, Salvia miltiorrhiza, policosanol, Camellia sinensis extract, Melannurca campana extract, Curcuma longa and curcuminoids, spirulina, chitosan, betaglucan, glucomannan, coenzyme Q10, astaxanthin, folic acid and orthosiphon. Uses of the invention

[0021] The invention also provides the compositions disclosed herein for use in the treatment or prevention of hypercholesterolemia or hyperlipidemia.

[0022] The invention also provides the use of the compositions disclosed herein for the manufacture of a medicament for the treatment or prevention of hypercholesterolemia or hyperlipidemia.

[0023] The invention also provides a method for the treatment or prevention of hypercholesterolemia or hyperlipidemia comprising administration of the compositions disclosed herein to a patient in need thereof.

[0024] Hypercholesterolemia (and hyperlipidemia) is a well-known risk factor for coronary artery, cerebrovascular and peripheral artery diseases. In fact, any reduction of basal cholesterol in plasma levels is correlated to a proportionally reduced incidence of cardiovascular complications (myocardial infarction, stroke, peripheral obstructive arterial disease). The correlation already exists before the first clinical event, relevant for primary prevention, as well as for the cardiovascular events that follow the first clinical vent, relevant for secondary prevention.

[0025] Dosage

[0026] The compositions of the invention are useful in the treatment or prevention of hypercholesterolemia, and hyperlipidemia.

[0027] The compositions are generally administered to a subject in need of such administration, for example a human or animal, typically a human. The compositions will typically be administered in amounts that are therapeutically or prophylactically useful.

[0028] The compositions may be administered over a prolonged term to maintain beneficial therapeutic effects or may be administered for a short period only.

[0029] A typical daily dose of each components of the combination can be in the range from 100 pg to 100 mg per kg of body weight, more typically 5 ng to 25 mg per kg of bodyweight, and more usually 10 ng to 15 mg per kg (e.g. 10 ng to 10 to 20 mg, and more typically 1 pg per kg to 20 mg per kg, for example 1 pg to 10 mg per kg) per kg of bodyweight although higher or lower doses may be administered where required.

[0030] The compositions may be administered orally in a range of doses, for example 0.1 to 1000 mg, 1 to 800 mg, 5 to 700 mg, 10 to 500 mg, 25 to 400 mg, or 50 to 350 mg.

[0031] Particular examples of daily doses of the composition are 100, 200, 300, 600, 900, 1200, 1500 and 1800 mg. For a composition of red yeast rice standardized in monacolin K to 1 .75% w / w, this dosage range typically corresponds to a daily dose of monacolin K of between 0.2 mg to about 35 mg.

[0032] The daily dose may be administered in a single daily dose, or multiple doses spread throughout the day e.g. once-daily, twice-daily or three-times daily.

[0033] Formulations

[0034] In one embodiment, the red yeast rice composition according to the invention e.g. a pharmaceutical composition is provided as an oral dosage form. Oral dosage forms include tablets (coated or uncoated), capsules (hard or soft shell), caplets, pills, lozenges, syrups, solutions, powders, granules, elixirs and suspensions, sublingual tablets, wafers or patches such as buccal patches. Therefore, in one embodiment of the invention, the red yeast rice composition according to the invention is presented in a tablet.

[0035] Typically, the tablet includes one or more pharmaceutically acceptable excipient. The pharmaceutically acceptable excipient can be selected from, for example, carriers (e.g. a solid, liquid or semi-solid carrier), adjuvants, diluents, fillers or bulking agents, granulating agents, coating agents, release-controlling agents, binding agents, disintegrants, lubricating agents, preservatives, antioxidants, buffering agents, suspending agents, thickening agents, flavouring agents, sweeteners, taste masking agents, stabilisers or any other excipients conventionally used in pharmaceutical compositions.

[0036] Preferably, the composition of the invention is formulated with one or more pharmaceutically acceptable fillers or bulking agents.

[0037] Examples of excipients include magnesium stearate, silicon dioxide, carboxymethylcellulose, crospovidone, and hydroxypropyl cellulose and maltodextrin.

[0038] In one embodiment, the red yeast rice composition is provided in capsules.

[0039] Typically, the capsule includes one or more pharmaceutically or nutraceutically acceptable excipient. The pharmaceutically or nutraceutically acceptable excipient can be selected from, for example, carriers (e.g. a solid, liquid or semi-solid carrier), adjuvants, diluents, fillers or bulking agents, granulating agents, coating agents, release-controlling agents, binding agents, disintegrants, lubricating agents, preservatives, antioxidants, buffering agents, suspending agents, thickening agents, flavouring agents, sweeteners, taste masking agents, stabilisers or any other excipients conventionally used in pharmaceutical compositions.

[0040] Examples of excipients include magnesium stearate, silicon dioxide, maltodextrin, carboxymethylcellulose, crospovidone, and hydroxypropyl cellulose.

[0041] Formulation example EXAMPLES STABILITY ANALYSIS OF RED YEAST RICE COMPOSITIONS The aim of the stability study was to compare the effect of different ratios of RYR and CaCO3 on the stability profiles of monacolin K comprising composition. Tablet preparation was done in the usual way. The following tablet compositions were analysed: 10 A RYR / CaCO3 in a ratio of 2 to 3 B RYR / CaCO3 in a ratio of 2 to 1 C RYR / CaCO3 in a ratio of 1 to 2 D RYR / CaHPO4 in a ratio of 1 to 2 Storage conditions were 25°C 65%RH, 30°C 75%RH, 40°C 75%RH Samples were analysed after 0, 3, 6, 12, 18 and 24 months 5 Results

[0042] The results demonstrate that the compositions comprising RYR and CaCO3have an improved stability, with respect to monacolin K concentration, compared to the composition comprising RYR and CaHPO4.

[0043] Especially stable are the compositions comprising RYR and CaCO3in a ratio of 2 to 3 and 1 to 2.

Claims

CLAIMS1 . A composition comprising red yeast rice and CaCO3.

2. The composition as claimed in claim 1 , characterized in that the ratio of red yeast rice andCaCO3is between 1 to 5 and 5 to 1 .

3. The composition as claimed in claim 1 , characterized in that the ratio of red yeast rice andCaCO3is between 1 to 2 and 2 to 3.The composition as claimed in claim 1 , characterized in that the ratio of red yeast rice andCaCO3is 2 to 3.

5. The composition as claimed in claim 1 , characterized in that the ratio of red yeast rice andCaCO3is 1 to 2.

6. The composition as claimed in claims 1 to 5, characterized in that the red yeast rice is standardized in monacolin K from 0.5 to 2.0 % w / w.

7. The composition as claimed in claims 1 to 6, characterized in that the red yeast rice is standardized in monacolin K 1 .75 % w / w.

8. The composition as claimed in any of claims 1 to 7 for use in the treatment or prevention of hypercholesterolemia or hyperlipidemia.

9. The composition as claimed in any of claims 1 to 8, additionally comprising one or more components selected from Berbens aristata, phytosterols and / or phytostanols, Cynara cardunculus extract, Citrus bergamia extract, Allium sativum, Salvia miltiorrhiza, policosanol, Camellia sinensis extract, Melannurca campana extract, Curcuma longa and curcuminoids, spirulina, chitosan, betaglucan, glucomannan.

10. The composition as claimed in any of claims 1 to 9, additionally comprising one or more components selected from coenzyme Q10, astaxanthin, folic acid, orthosiphon.